---
document_datetime: 2025-10-03 11:58:22
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ogsiveo-epar-all-authorised-presentations_en.pdf
document_name: ogsiveo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.2021926
conversion_datetime: 2025-12-22 16:23:30.676216
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging    | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|------------------------|-------------|
| EU/1/25/1932/001 | Ogsiveo           | 50 mg      | Film-coated tablet    | Oral use                  | bottle (HDPE)          | 120 tablets |
| EU/1/25/1932/002 | Ogsiveo           | 50 mg      | Film-coated tablet    | Oral use                  | bottle (HDPE)          | 180 tablets |
| EU/1/25/1932/003 | Ogsiveo           | 100 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 56 tablets  |
| EU/1/25/1932/004 | Ogsiveo           | 150 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 56 tablets  |